{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:23:38Z","timestamp":1783441418220,"version":"3.54.6"},"reference-count":22,"publisher":"Bioscientifica","issue":"8","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":193,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to determine serum I-309 levels in type 2 diabetes mellitus (T2DM) patients, as well as the association with clinical\/laboratory phenotypes and disease complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 155 T2DM patients and 30 healthy controls (HC) were enrolled. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-10, IL-12, IL-17, IL-23, tumor necrosis factor-\u03b1 (TNF-\u03b1), and interferon (IFN)-\u03b3 were measured. The relationships between I-309 and various clinical and laboratory variables were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The serum concentrations of I-309 were significantly higher in T2DM patients than in HC (P &amp;lt; 0.001). The serum I-309 levels were significantly elevated in T2DM patients with diabetic kidney disease (DKD), hypertension, coronary artery disease, peripheral neuropathy, peripheral artery disease, and diabetic ketosis (all P &amp;lt; 0.05), but reduced in drinkers (P = 0.018). The Spearman analysis showed that serum I-309 correlated positively with age, disease duration, CKD stages, urea, creatinine, urinary albumin-to-creatinine ratio, C-reactive protein, red blood cell distribution width, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, IL-6, IL-12, and IFN-\u03b3, but negatively with estimated glomerular filtration rate (eGFR), fasting blood glucose, total bilirubin, albumin, lymphocyte count, red blood cell count, and hemoglobin. The multiple linear regression analysis indicated that serum I-309 was independently correlated only with eGFR and IFN-\u03b3. The multivariate logistic regression analysis demonstrated that serum I-30 and IL-17A remained independently associated with DKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum I-309 is markedly elevated in T2DM patients and is associated with increased DKD risk, suggesting its potential role as both a promising biomarker and a pathogenic mediator in the progression of T2DM, particularly DKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0252","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T12:20:08Z","timestamp":1755519608000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":0,"title":["Association of increased serum I-309 with renal function impairment and diabetic kidney disease in type 2 diabetes mellitus"],"prefix":"10.1530","volume":"14","author":[{"given":"Bing","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People\u2019s Hospital 1 , , ,","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People\u2019s Hospital 1 , , ,","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Management Center, Changzheng Hospital, Naval Medical University 2 , ,","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Changzheng Hospital, Naval Medical University 3 , ,","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7545-642X","authenticated-orcid":true,"given":"Zaixing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People\u2019s Hospital 1 , , ,","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2026070711015415100_bib1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00125-018-4658-3","article-title":"Novel approaches to restore beta cell function in prediabetes and type 2 diabetes","volume":"61","author":"Salunkhe","year":"2018","journal-title":"Diabetologia"},{"key":"2026070711015415100_bib2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","article-title":"Insulin resistance in type 2 diabetes mellitus","volume":"21","author":"Accili","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"2026070711015415100_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13098-024-01369-x","article-title":"Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes","volume":"16","author":"Guan","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"2026070711015415100_bib4","article-title":"Overview of oxidative stress and inflammation in diabetes","volume":"16","author":"Weinberg","year":"2024","journal-title":"J Diabetes"},{"key":"2026070711015415100_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151431","article-title":"Role of inflammation in progression of chronic kidney disease in type 2 diabetes mellitus: clinical implications","volume":"43","author":"Oda","year":"2023","journal-title":"Semin Nephrol"},{"key":"2026070711015415100_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026070711015415100_bib7","article-title":"Immune responses in diabetic nephropathy: pathogenic mechanisms and therapeutic target","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2026070711015415100_bib8","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.immuni.2021.06.008","article-title":"The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis","volume":"54","author":"Liu","year":"2021","journal-title":"Immunity"},{"key":"2026070711015415100_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ado2463","article-title":"CCR8(+) decidual regulatory T cells maintain maternal-fetal immune tolerance during early pregnancy","volume":"10","author":"Li","year":"2025","journal-title":"Sci Immunol"},{"key":"2026070711015415100_bib10","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1084\/jem.20182111","article-title":"A CCL1\/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2-mediated inflammation","volume":"216","author":"Knipfer","year":"2019","journal-title":"J Exp Med"},{"key":"2026070711015415100_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/jpm14070743","article-title":"The role of pro-inflammatory chemokines CCL-1, 2, 4, and 5 in the etiopathogenesis of type 2 diabetes mellitus in subjects from the Asir Region of Saudi Arabia: correlation with different degrees of obesity","volume":"14","author":"Mir","year":"2024","journal-title":"J Personalized Med"},{"key":"2026070711015415100_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/sji.12637","article-title":"Activity of group 2 innate lymphoid cells is associated with chronic inflammation and dysregulated metabolic homoeostasis in type 2 diabetic nephropathy","volume":"87","author":"Lu","year":"2018","journal-title":"Scand J Immunol"},{"key":"2026070711015415100_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3158","article-title":"Standards of medical care for type 2 diabetes in China 2019","volume":"35","author":"Jia","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"2026070711015415100_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026070711015415100_bib15","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"KDOQI","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026070711015415100_bib16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026070711015415100_bib17","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.4049\/jimmunol.179.9.5760","article-title":"Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1","volume":"179","author":"Cantor","year":"2007","journal-title":"J Immunol"},{"key":"2026070711015415100_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.humimm.2014.02.007","article-title":"The alteration of Th1\/Th2\/Th17\/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy","volume":"75","author":"Zhang","year":"2014","journal-title":"Hum Immunol"},{"key":"2026070711015415100_bib19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cca.2010.01.036","article-title":"Aberrant cytokines\/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy","volume":"411","author":"Wu","year":"2010","journal-title":"Clin Chim Acta"},{"key":"2026070711015415100_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3923\/pjbs.2009.746.749","article-title":"Evaluation of IFN-gamma serum level in nephropatic type 2 diabetic patients","volume":"12","author":"Nosratabadi","year":"2009","journal-title":"Pak J Biol Sci"},{"key":"2026070711015415100_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.trsl.2015.04.013","article-title":"Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression","volume":"166","author":"Kim","year":"2015","journal-title":"Transl Res"},{"key":"2026070711015415100_bib22","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/nep.14396","article-title":"Heat shock protein 70 promotes the progression of type 2 diabetic nephropathy by inhibiting T-cell immunoglobulin and mucin domain-3 and thereby promoting Th17\/Treg imbalance","volume":"29","author":"Zhang","year":"2024","journal-title":"Nephrology"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/8\/EC-25-0252.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/8\/EC-25-0252.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0252\/9937\/ec-25-0252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0252\/9937\/ec-25-0252.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:38:01Z","timestamp":1783438681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/8\/e250252\/1458\/Association-of-increased-serum-I-309-with-renal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0252","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"e250252"}}